Stay up to date with the latest health and social care news from across the UK. From children’s mental health crisis and new inspection guidance for prison education to women’s mental health after childbirth and employment reforms affecting UK employers, discover the stories and developments shaping the sector.
NHS England is progressing plans to test alternative funding arrangements designed to give patients faster and fairer access to innovative medicines, particularly where local financial pressures have delayed the introduction of treatments already recommended for NHS use.
The initiative forms part of a wider programme developed by the government, NHS England, the pharmaceutical industry and patient organisations to address inequalities in access to new treatments. It aims to ensure that patients are not disadvantaged simply because of where they live or the financial circumstances of their local NHS services.
Although medicines approved by the National Institute for Health and Care Excellence (NICE) are recommended nationally, their adoption can vary between areas. Integrated care boards (ICBs), which commission many NHS services, face different financial pressures that can influence how quickly eligible patients receive treatment.
The pilot will initially focus on innovative medicines for chronic obstructive pulmonary disease (COPD), chronic kidney disease and heart failure. These conditions affect substantial numbers of people and can significantly reduce quality of life, particularly among older adults and those living with multiple health conditions.
NHS England has confirmed that participating regions will be selected through an application process, with the programme expected to begin in April 2027 and operate for two years. The trials will examine whether reducing local affordability barriers improves access, increases treatment uptake and produces better outcomes for patients.
The programme follows wider changes to the assessment of innovative medicines, including adjustments to NICE’s cost-effectiveness threshold earlier this year. The government reported in July that nine additional medicines had been approved following those changes, including treatments for cancers, autoimmune conditions and blood disorders.
For patients and families, the potential benefits extend beyond access to medication. Earlier treatment may help prevent deterioration, reduce avoidable hospital admissions and support people to maintain their independence for longer.
The initiative could also have implications for social care services, particularly where effective treatment reduces the level of assistance people require with everyday activities. However, these wider benefits will need to be demonstrated through the pilot rather than assumed.
NHS England intends to monitor participating regions and assess whether alternative funding models deliver more consistent access to medicines. The findings could inform future national policy on how innovative treatments are funded and introduced across the health service.
While the programme remains in its preparatory stages, it represents an attempt to address a longstanding concern: that approval of a treatment does not always mean patients can access it equally or promptly across England.
Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.
Posted by:
M Ramalani
Editorial Assistant – The Daily Round
Busy day? We’ve got you covered. Get FREE daily news, practical insights, opportunities and wellbeing content, carefully curated for busy health and social care professionals. Just enter your details below to get The Daily Briefing delivered straight to your inbox.
Busy day? We’ve got you covered. Get FREE daily news, practical insights, opportunities and wellbeing content, carefully curated for busy health and social care professionals. Just enter your details below to get The Daily Briefing delivered straight to your inbox.